Objectives/Hypothesis: Assess tumor suppressor p53 (TP53) functional mutations in the context of other biomarkers in advanced larynx cancer.
INTRODUCTION
Larynx cancer is diagnosed in 12,260 patients in the United States each year, causing 3,630 deaths. 1 The high morbidity associated with the traditional surgical treatments led to the development of larynx-sparing chemoradiotherapy regimens. 2, 3 Furthermore, many biomarkers have been studied in attempts to better classify patients for different treatment modalities and increase their survival. 4 The tumor suppressor p53 (TP53) is mutated in up to 60% of head and neck cancers in some series. 5 It has a central role in determining cell fate in response to stressors. [6] [7] [8] [9] [10] The role of p53 as a prognostic biomarker in larynx cancer is controversial. Some studies show an association of p53 mutations with better sensitivity to chemotherapy, 11 whereas others associate it with poor response. 12, 13 Almost 75% of the TP53 mutations reside in the DNA-binding domain, and more than 30% are in one of six hotspot codons. These mutations can promote cancer development. Thus, analysis based primarily on protein function is appropriate in assessing clinical outcome linked to p53 mutants rather than only on its expression, as frequently was done in the past. Functional classifications of p53 can be based on Evolutionary Action score of TP53 (EAp53), 14 yeast-based transcriptional activity, 15 and published gain of function (GOF) mutations.
In larynx cancer, B-cell lymphoma-extra large (Bclxl) and cyclin D1 are predictors of response to therapy and survival that are linked to p53 status. 4, 16 Bcl-xl is an anti-apoptotic protein member of the Bcl-2 family [17] [18] [19] that inactivates proapoptotic proteins at the mitochondrial membrane. 19, 20 Cyclin D1 phosphorylates and inactivates retinoblastoma protein (Rb), allowing cell cycle progression.
Human papillomavirus (HPV) studies in larynx cancer have been limited to recurrent laryngeal papillomatosis, which is caused by infection with lowrisk HPV types 6 and 11. 21 High-risk HPV (hrHPV), especially HPV16, has become increasingly common in head and neck cancer. [22] [23] [24] [25] [26] [27] In the current study, we assess the role of hrHPV, TP53 functional classifications, Bcl-xl, and cyclin D1, each as a single variable factoring outcome as well as part of a multivariable model for advanced larynx cancer outcome.
MATERIALS AND METHODS

Study Population
The UMCC9520 larynx-sparring cancer trial enrolled 97 patients with stage III and IV squamous cell carcinoma of the larynx. Adequate pretreatment biopsy tissue was available for DNA isolation from 58 of 97. A detailed description of the clinical trial was previously reported. 3 
Tissue Handling and DNA Extraction
Tumor tissue was obtained from formalin-fixed paraffinembedded pretreatment biopsies. A head and neck pathologist marked representative areas of tumor. Two cores were taken from the marked areas using a 20-gauge needle. DNA was extracted using the QiaAmp DNA Mini Kit (Qiagen, Valencia, CA). DNA quantity and quality were corroborated with ultraviolet-visible spectrophotometer using a NanoDrop ND-1000 (NanoDrop Technologies, Wilmington, DE).
TP53 Sequencing
TP53 mutations were assessed by polymerase chain reaction (PCR) amplification of exons 4 to 9 and subsequent DNA sequencing. Seven pairs of primers were used (Supp . Table SI) with AmpliTaq DNA Polymerase (Invitrogen, Life Technologies, Grand Island, NY), as indicated by the manufacturer. Amplification was performed at 958C for 10 minutes, 36 cycles of 958C for 30 seconds, 608C for 30 seconds, 728C for 45 seconds, and a final extension at 728C for 10 minutes. The amplicons were examined with electrophoresis in a 1.5% agarose gel, purified using the Wizard SV Gel (Promega Corporation, Madison, WI) and PCR Clean-Up System (Promega Corporation), and submitted to the University of Michigan DNA Sequencing Core for bidirectional sequencing. Mutations were confirmed with a second independent PCR reaction and sequencing.
TP53 Mutant Classifications
Three classifications designed to classify TP53 single-base pair mutations (point mutations) were studied. The EAp53 classification that was designed and validated for head and neck cancers 14 scores TP53 mutations as high-risk mutations (H) and low-risk mutations (L) obtained through a computational algorithm based on evolutionary sensitivity and amino acid conservation. Tumors without mutations were designated as wild type (W) TP53. Insertion/deletions were not scored.
The p53 transactivation activities (TAs) classification is based on reporter gene activity placed under the control of eight p53 response elements in yeast models. 15 Transactivation activities were measured as a percentage of W p53 TA and classified as supertrans (median TA above 140%), functional (median TA of 76%-140%), partially functional (median TA of 21%-75%), and nonfunctional (median TA below or equal 20%). 15, 28 The p53 mutant GOF classification is compared to mutants with no evidence of GOF and W TP53. The p53 GOF mutations have been defined as those with activities independent and unrelated to W protein. 15 These activities were demonstrated by RNA interference silencing or direct transfection of the mutant TP53. 29 To identify GOF mutants, a literature search of PubMed without language limitation was performed using the search terms "mutant p53" and "gain of function." Additionally, every missense mutation in this study was used as a search term to find reports.
HPV Testing
DNA samples from the pretreatment biopsies were analyzed for the presence of high-risk HPV using the multiplex HPV PCR-MassArray assay as described. 25 Bcl-xl, Cyclin D1, and p16INK4a Immunohistochemistry
Staining intensity (scale: 1: none, 2: weak, 3: moderate, and 4: strong) and proportion (scale 1: < 5% staining, 2: 5%-20% staining, 3: 21%-50% staining, and 4: 51%-100% staining) were assessed by immunohistochemistry using a tissue microarray and scored by a head and neck pathologist (J.B.MCH.) blinded to patient outcome, as previously described.
4,25
Statistical Analysis
Associations between TP53 groups and clinical characteristics were assessed using v 2 statistics. Correlations with induction chemotherapy response, overall survival (OS), diseasespecific survival (DSS), and time to indication for surgery (TIS) were tested by log-rank tests and logistic and Cox proportional hazards regression models. Time-to-event outcomes (OS, DSS, TIS) were measured from date of diagnosis. For illustration in figures, Bcl-xl and Cyclin D1 intensity scores were grouped as no (1), low (2), and high (3 or 4). Multivariable analyses controlling for stage, smoking, and hrHPV were performed using logistic and Cox proportional hazards models. Variables tested included TP53 mutational status and presence of hrHPV DNA, Bcl-Xl, and CyclinD1 expression.
RESULTS
Sample Characteristics
TP53 sequence and clinical data were obtained from a previously published study. 3 Basic clinical and tumor characteristics are shown in Table 1 .
TP53 Mutants
Of the 97 eligible patients, TP53 gene was sequenced in 58. Of these, 22 tumors contained TP53 mutations. Five (8.6%) had deletions that were not classifiable. Fiftythree patients classified had either W TP53 (36 of 53 [68%]) or single-base changes (17 of 53 [32%]) corresponding to missense in 13 of 53 (24.5%) or non-sense mutations in four (7.5%). No insertions were found. A TP53 missense mutational spectrum is presented in Supporting Table SII . Bivariate associations were tested for each p53 classification with age, T stage, N stage, smoking, and HPV. The EAp53 classification 14 revealed a significant association of H mutations and node-positive tumors (P 5 0.03) ( Table 2 ). Seven (53.8%) of the 13 missense mutations were classified as GOF. No significant associations with clinical parameters were found for GOF or transactivation classifications, L, and W.
HPV and p16INK4a
Tumor DNA from 52 patients was analyzed with the multiplex HPV PCR-MassArray assay. 25 High-risk HPV was identified in 20 of 52 (38. 
TP53 Mutants and Induction Chemotherapy
Thirty-eight of the 58 patients (66%) responded to induction chemotherapy (tumor volume decrease > 50%). Multivariable logistic regression models with different models, including T stage and N stage separately, overall stage, HPV, and smoking, were run. No significant predictors of response to induction chemotherapy were found in any of the TP53 classifications. 
TP53 Mutants and Survival
Of the 58 patients with a median follow-up of 95 months, the Kaplan-Meier estimates for overall survival at 1, 2, and 5 years were 90%, 83% and 67%, respectively. Disease-specific survival estimates were 91%, 86%, and 80%, respectively.
Using the EAp53 classification and univariate analysis (log-rank tests), we find a significant DSS difference between strata (P 5 0.026) (Fig. 1) . Pairwise, the difference between the H versus L groups was significant (P 5 0.027). The differences between H versus W (P 5 0.188) and L versus W (P 5 0.988) groups were not statistically significant. Using a Cox model after controlling for T stage, N stage, and HPV status, the effect of p53 mutation was no longer significant (P 5 0.114). No significant differences were observed for DSS using the yeast assay-based classification (P 5 0.603, log-rank; P 5 0.887 Cox) or GOF classification (P 5 0.096 log-rank; P 5 0.130 Cox). Interestingly there was a trend for the GOF mutations to do better.
TP53 Mutants and Time to Surgery
Time to indication for surgery (TIS) was evaluated for the TP53 classifications. No significant differences in TIS were found between groups using the EAp53, yeast transcriptional assay-based, or GOF classifications (P 5 0.654, P 5 0.394, and P 5 0.835, respectively). After controlling for stage, smoking, and HPV status, the differences were still not significant (P 5 0.667, P 5 0.245, P 5 0.874, respectively).
HPV, p16INK4a, Bcl-xL, and Cyclin D1: Effects on the EAp53 Classification and Survival
The role of HPV, p16INK4a, Bcl-xL, and cyclin D1 in the EAp53 classification was assessed. As a single variable, the presence of HPV did not reach significance (logrank P 5 0.38) When separating the HPV-positive tumors by p16INK4a status, we found that the patients with HPV1/p16INK4a1 tumors tended to have a better DSS compared to the HPV1/p16INK4a-and HPV-negative. This difference did not reach statistical significance (longrank P 5 0.4037 and P 5 0.3506, respectively) ( Fig. 2A) . No patients with HPV1/p16INK4a1 tumors die due to cancer. By including only the HPV-positive cases with W TP53, we observed that HPV-positive W TP53 patients tended to have better DSS than the HPV-negative patients. This difference did not reach statistical significance (P 5 0.195) (Fig. 2B) .
We found no evidence of an association between Bcl-xL intensity in different TP53 groups. In multivariable analysis, Bcl-xL expression displayed a trend for poorer DSS (P 5 0.075) ( Table 3) . By plotting the DSS of the TP53 groups and sorting out the W TP53 based on their biomarker status, we found no significant difference across Bcl-xL staining intensities. However, the group with W TP53 and no expression of Bcl-xL had no deaths due to cancer (Fig. 2C.) .
Alone, cyclin D1 was associated with poor DSS (HR 2.4, P 5 0.010 Cox). When sorting the W TP53 by cyclin D1 staining intensity, we found that high-cyclin D1 staining was a predictor of poor survival compared with low-or no cyclin D1 staining (P 5.051 and P 5 0.044, respectively) (Fig. 2D. ) Cyclin D1 showed a trend (P 5 0.096) for higher intensity in the high-risk group of p53 mutations.
Multivariable Model for Prediction of Survival
A model with Bcl-xL, cyclin D1, EAp53 classification, and hrHPV status was highly significant as a prognostic model for DSS (P 5.002, likelihood ratio test) ( Table 3 ). A full model including EAp53 classification of TP53, Bcl-xL intensity, cyclin D1 intensity, stage, smoking status, and HPV status was also performed (Supp . Table SIII) . This model was significant for modeling DSS (P 5 0.011), although a backward selection algorithm suggested dropping stage and smoking for a better model. We found no significant models for induction chemotherapy response or to time to indication for surgery.
DISCUSSION
Three classifications for TP53 mutations were analyzed. Only the EAp53 classification 14 based on mutant TP53 transcriptional activity showed clinical significance. This classification predicted DSS (P 5 0.026). In this clinical trial, patient selection through induction chemotherapy resulted in larynx preservation in 70% of patients and DSS of 87%. 3 Although patient survival was improved, there was still a subset of patients with poor outcome. The EAp53 classification has potential to identify this subset of patients.
Bivariate associations were tested for EAp53 classification with age, T stage, N stage, smoking status, hrHPV, Bcl-xL, and cyclin D1 staining. Of interest, high-risk mutations found by EAp53 classification were associated with lymphatic metastasis at presentation (P 5 0.03) and a trend for high expression of cyclin D1 (P 5 0.096). It is known that node-positive patients have poorer survival. 30 Therefore, EAp53 classification could potentially guide therapeutic approaches such as neck dissection, neck irradiation, or the addition of chemotherapy to radiation treatment. More aggressive treatment to the neck of patients with high-risk TP53 mutations could improve patient outcome. We also found a trend for high-risk TP53 mutants to have high expression of cyclin D1. Cyclin D1 was previously found to be associated with overall and disease-specific survival. 4 We propose a mechanism in which cyclin D1 overexpression is unchecked by defective p53. High-risk TP53 mutations have a lower expression of BTG2 (B-cell translocation gene 2) protein compared to their W and low-risk counterparts.
14 BTG2 inhibits cyclin D1 transcription. 31, 32 Thus, its low expression is a likely mechanism for cyclin D1 overexpression. Furthermore, cyclin D1 itself could be constitutively overexpressed by dysregulation in the b-catenin, 33,34 RAS/MAPK, or IP3K pathways. 35 The EAp53 classification and cyclin D1 have proven to be powerful predictors of survival in advanced larynx cancer patients, but further studies are needed to characterize the cellular mechanisms by which these markers interact and affect survival in this type of cancer.
Gain of function mutations affect important cellular activities such as proliferation, apoptosis, chemoresistance, metabolism, cell-to-cell interactions, or cytoskeleton conformation. 29 Only seven of 58 (12%) of the sequenced patients had a TP53 GOF mutation. These showed no impact on response to induction chemotherapy, time to surgery, or survival. We grouped all GOF mutations together. More specific classification of GOF mutations based on the cellular functions altered could offer a better understanding of how these mutations affect patient outcome. Larger studies and a more comprehensive GOF classification are needed for assessment of their impact in larynx cancer.
The proportion of tumors with mutant TP53 (22 of 58 [37.9%]), was lower than expected 36 TP53 mutations are uncommon in HPV-positive tumors. 37 The low rate of TP53 mutations in this study is consistent with the high proportion of hrHPV-positive larynx tumors, (20 of 52 [38.5%] ), that we found. This is also consistent with previous reports of HPV in up to 25% of larynx carcinomas, 38, 39 and with the increasing frequency of HPVrelated head and neck cancers in general. 40, 41 A recent report from the Tissue Cancer Genome Atlas (TCGA) head and neck cancer group included 72 larynx cancer cases. From these, 66 of 72 (91.6%) have mutated TP53, and only five of 72 (7%) are HPV PCR-MassArray-positive. 42 Patient selection could be causative of the discrepancy found between the studies. Although samples in the TCGA study were collected without regard to disease stage or patient functional status, in our study patients were part of a clinical trial and were selected with a good functional status and an advanced stage of disease (stage III and IV). 3, 42 Differences in geographical distribution of the patients could be another factor affecting the HPV detection rates; geographic variability of HPV-related HNSCC have been reported. 43, 44 The biology of the HPV-positive tumors was assessed using p16INK4a immunohistochemistry. P16INK4a status did not correlate with HPV status (Rho 5 0.09), showing a dichotomy of HPV-related larynx cancer. All HPVpositive tumors with p16INK4a-positive staining presented a W TP53 and showed a better DSS with zero deaths caused by cancer. These HPV-related tumors show characteristics of the typical HPV E6-and E7-driven cancers. A different subset of HPV-positive tumors with p16INK4a-negative staining did not show a clear correlation with TP53 mutational status, and patients presented a DSS similar to the HPV-negative patients (Fig. 2A) . Further studies addressing other mechanisms of HPV carcinogenesis, such as viral DNA integration, methylation profiling, miRNA profiling, and characterization of other HPV-related cellular pathways, will determine the role of HPV in this subset of HPV-positive larynx tumors.
Kumar et al., 16 in their analysis of the Department of Veterans Affairs (VA) Laryngeal Cancer Trial, 2 found that low Bcl-xL and high p53 staining were predictors of larynx preservation in patients treated with induction chemotherapy followed by definitive radiation. Here, we found no significant effect of Bcl-xL on clinical outcome, although in multivariable analysis a trend was noted for poorer disease-specific survival to be associated with BclxL expression. The association with organ preservation was not explored in this analysis. It is interesting to note that among WTp53 patients with no Bcl-xL expression, no tumor failures were seen. We observed a similar trend to improved survival with Bcl-xL expression in the VA Study. Both studies gave induction chemotherapy (cisplatin 100 mg/m2 on day 1 and fluorouracil 1,000 mg/m2/day for 5 days). In the VA study, tumor response was assessed after two cycles of induction, and responders went on to an additional cycle of chemotherapy followed by radiotherapy alone. 2 In contrast, in UMCC9520 a single round of the same induction therapy was followed by response assessment, and either immediate surgery/radiotherapy (nonresponders) or radiotherapy with concurrent cisplatin (100 mg/m2) given on day 1, 22, 43. 3 The addition of concurrent cisplatin to radiation in UMCC9520 could change the association of Bcl-xL expression as a biomarker of outcome. Recent studies suggest that cisplatin can activate extrinsic apoptotic pathways or induce necrosis 45 or cell senescence. 46 In these scenarios, cell death is no longer completely dependent on the intrinsic mitochondrial apoptotic machinery, 47 which could explain the loss of power for Bcl-xL as a predictive biomarker. Nonetheless, the importance of a functional intrinsic apoptotic pathway in the response to chemoradiotherapy is evidenced by the fact that, in our study patients, whose tumor did not stain for the apoptotic inhibitor Bcl-xL and had W TP53 did not die due to cancer (Fig. 2C) .
We constructed a model for the prediction of diseasespecific survival based on a combination of biomarkers and clinical characteristics. The model including classification of TP53, Bcl-xL intensity, cyclin D1 intensity, stage, smoking status, and HPV status was able to predict survival (P 5 0.011). By including only variables with a strong predictive value (i.e., Bcl-xL, cyclin D1, p53 mutation classification, and HPV status), we obtained a selected model that was highly significant for the prediction of disease-specific survival (P 5 0.0017) (Likelihood Ratio Test Table III ). In this model, we can distinguish two types of patients: 1) high-risk TP53 mutation was predictive of poor DSS; and 2) low-risk TP53 mutation was predictive of good DSS (P 5 0.026) (Fig. 1.) . In patients with W TP53, high staining of cyclin D1 was predictive of poor DSS, whereas no/low staining for cyclin D1, no staining for Bcl-xL, and HPV positivity were predictors of good DSS (Fig. 2) (Supp . Table SIV) . Thus, treatment modalities targeting p53 and cyclin D1 could increase survival in advanced larynx cancer patients that fail to respond to current treatment. Novel targeted therapies such as mutant p53 reactivating small molecules; mdm2 inhibitors; cyclin-dependent kinase inhibitors; or inhibitors of b-catenin, RAS/MAPK, or IP3K pathways could potentially counteract these markers and offer better outcome. The model should be tested in larger cohorts.
CONCLUSION
A functional classification of TP53 mutants based on EAp53 predicts DSS in advanced larynx cancer patients with mutant TP53. A high proportion of hrHPV-related larynx cancers in this cohort reflects the epidemic of HPV-related head and neck cancers. A dichotomy in the biology of hrHPV is observed in larynx cancer. A model including Bcl-xL staining, cyclin D1 staining, p53 mutation classification, and HPV status was highly significant for predicting disease-specific survival. High-cyclin D1 expression and high-risk TP53 mutations were associated with poor DSS. New therapies targeting these pathways could benefit patients that fail to respond to current treatment modalities.
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